The widespread use of antidepressants for managing irritable bowel syndrome may carry previously unrecognized mortality risks that challenge current treatment paradigms. This finding emerges from the largest analysis to date examining long-term safety outcomes in IBS management, potentially affecting millions of patients worldwide who rely on these medications for symptom control.
Analysis of nearly 670,000 IBS patients revealed that antidepressant therapy increased all-cause mortality risk by 35 percent compared to non-users, with death rates climbing from 1.0% to 1.6%. This elevated risk persisted across all major antidepressant classes and remained consistent regardless of patient age, gender, or demographic factors. Among diarrhea-predominant IBS patients, anti-diarrheal medications loperamide and diphenoxylate showed even more concerning mortality increases of 139% and 89% respectively. Conversely, antispasmodic medications demonstrated neutral safety profiles with no mortality elevation.
These findings warrant careful reconsideration of IBS treatment algorithms, particularly given that antidepressants represent first-line therapy recommendations in major clinical guidelines. The mortality signal appears robust given the study's massive scale and propensity-matched design, though the observational nature prevents definitive causal attribution. The mechanism underlying increased mortality remains unclear—whether through direct drug effects, underlying patient characteristics, or treatment-resistant disease severity. This represents the first comprehensive mortality assessment for IBS pharmacotherapy, filling a critical evidence gap. Clinicians may need to weigh these mortality risks more heavily against symptom relief benefits, especially in younger patients where absolute mortality risk remains low but relative increases prove substantial.